Publication: 4691

Publication: 4691

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated with Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Controlled Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: JAMA Oncol vol 12 (2) 149-58

Year:: 2026
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: Other-NOS
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 15

Parents:: 4510 4637
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Pfizer, Natera (CSC0218)
Grants:: U10CA180821, U10CA180882, U24CA196171, UG1CA189830, UG1CA233180, UG1CA233339; U10CA180863, CCS 707213 (CCTG); U10CA180794, U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG Oncology); U10CA180888, UG1CA233163 (SWOG), T32 CA009001 (Zhang)

Corr. Author:
Authors:: George Q. Zhang Jeffrey A. Meyerhardt Qian Shi Tyler Twombly Levi Pederson Chao Ma Juha P. Väyrynen Melissa Zhao Yasutoshi Takashima Ardaman Shergill Pankaj Kumar Felix Couture Philip Kuebler Smitha Krishnamurthi Benjamin Tan Eileen M. O'Reilly Marios Giannakis Shuji Ogino Adham Jurdi Shruti Sharma Alexey Aleshin Anthony F. Shields Jonathan A. Nowak

Networks:: HEARTLAND, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NY016, NY141, OH027

Study: CALGB-80702
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: